Market Overview

Esperion Surge May Be Fueled By Repatha Short Squeeze

Esperion Surge May Be Fueled By Repatha Short Squeeze
Related ESPR
25 Stocks Moving In Monday's Pre-Market Session
28 Stocks Moving In Wednesday's Pre-Market Session
Biotechs Approaching New Waters (Seeking Alpha)
Related AMGN
Biotech Winners And Losers From Congress' Latest Funding Bill
The Week Ahead In Biotech: Earnings, PDUFA Dates And More
FDA OKs Sun Pharma's Ilumya for plaque psoriasis (Seeking Alpha)

Esperion Therapeutics Inc (NASDAQ: ESPR) has maintained its upward momentum on Tuesday, surging higher by another 13.2 percent. While the massive 80 percent runup since January 30 was triggered by positive fundamental news, a major short squeeze may be fueling the stock's enduring momentum.

On February 3, Amgen, Inc. (NASDAQ: AMGN) reported that PCSK9 inhibitor Repatha met both its primary and secondary endpoints in its FOURIER trial to determine if the drug can reduce cardiovascular events in patients with cardiovascular disease. While quantitative data wont' be available until March, Amgen reported Repatha “significantly reduced the risk of cardiovascular events,” news that sent shares of Esperion surging 24 percent. Traders are betting that Amgen's data is good news for Esperion's ETC-1002 drug candidate.

Short sellers were also likely spooked by several analyst upgrades and bullish comments following the news. Even after the 80 percent gain, JMP Securities still sees more than 100 percent upside for Esperion.

However, the positive development also likely sent short sellers running for the hills ahead of the March data release. According to, Esperion has an elevated short percent of float of 20.3 percent. There are currently more than 2.7 million shares held short with 7.8 days to cover.

Shorts that don’t take the opportunity to cover between now and the official data release are running the risk that Amgen's data will send Esperion's stock soaring to new highs. With a sizable short position still open, the Repatha-related short squeeze may continue in the days ahead.

Posted-In: Repatha Short SqueezeBiotech Long Ideas Short Ideas Movers Trading Ideas General Best of Benzinga


Related Articles (AMGN + ESPR)

View Comments and Join the Discussion!